FDA approves expanded label for Regeneron/Sanofi’s DupixentAnalysts, Approvals, Asthma, Atopic Dermatitis (Eczema), Biologics, Blockbusters, Chronic Obstructive Pulmonary Disease (COPD), Chronic Rhinosinusitis, Corticosteroids, Environmental Allergies, Eosinophilic Esophagitis, Expanded Label, FDA, FDA/Regulatory, Food Allergies, Nasal PolypsThe U.S. Food and Drug Administration approved Regeneron Pharmaceuticals Inc. and Sanofi SA’s drug Dupixent to treat nasal polyps, marking the third major use for the injectable medicine. Read more June 26, 2019/by Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Reuters Health2019-06-26 13:50:282019-06-27 13:19:47FDA approves expanded label for Regeneron/Sanofi’s Dupixent